Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape
- PMID: 36305867
- DOI: 10.1158/1078-0432.CCR-22-2853
Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape
Abstract
Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs, patient-derived xenograft models from human brain metastases and phase 0 and window-of-opportunity trials are of utmost importance. See related article by Kabraji et al., p. 174.
©2022 American Association for Cancer Research.
Comment in
-
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138. Clin Cancer Res. 2023. PMID: 36074155 Free PMC article.
Comment on
-
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138. Clin Cancer Res. 2023. PMID: 36074155 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous